Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study by Yoshihito Kogure, MD, PhD, Akiko Kada, MPH, Hiroya Hashimoto, PhD, Shinji Atagi, MD, Yuichi Takiguchi, MD, Hideo Saka, MD, Noriyuki Ebi, MD, Akira Inoue, MD, Takayasu Kurata, MD, Yuka Fujita, MD, Yoichi Nishii, MD, Hidetoshi Itani, MD, Takeo Endo, MD, Akiko M. Saito, MD, Takuo Shibayama, MD, Nobuyuki Yamamoto, MD, Akihiko Gemma, MD

Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

Get full text